反应详情

To a mixture of 150 mg of 4-oxo-8-(tetrahydrofuran-3-ylmethoxy)-1-(tetrahydro-2H-pyran-4-yl)-4,5-dihydroimidazo[1,5-a]quinoxaline-7-carboxylic acid and 3 mL of N,N-dimethyl formamide were sequentially added 122 mg of 5-bromo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine, 0.25 mL of N,N-diisopropylethylamine, and 220 mg of HATU, followed by stirring at room temperature for 72 hours. The mixture was poured into a cooled saturated aqueous sodium hydrogen carbonate solution, followed by stirring for 30 minutes and extracting with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform/methanol=100/0-92/8) to obtain 81 mg of 7-[(5-bromo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)carbonyl]-8-(tetrahydrofuran-3-ylmethoxy)-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-4(5H)-one as a white solid.

1. stirringby stirring for 30 minutes
2. extractionextracting with ethyl acetate
3. washThe organic layer was washed with saturated brine
4. dry with materialdried over anhydrous magnesium sulfate
5. customThe solvent was evaporated under reduced pressure
6. customthe residue was purified by silica gel column chromatography (chloroform/methanol=100/0-92/8)